-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell reports 16.6-month median survival in Phase 2 Bria-IMT regimen for metastatic breast cancer patients at ASCO 2026

PUBT·06/01/2026 11:34:05
Listen to the news
BriaCell reports 16.6-month median survival in Phase 2 Bria-IMT regimen for metastatic breast cancer patients at ASCO 2026
  • Briacell highlighted new clinical updates on its Bria-IMT regimen for late-stage metastatic breast cancer at the 2026 ASCO meeting.
  • Final Phase 2 findings were already presented, pointing to longer survival for a subset of heavily pretreated patients with manageable side effects.
  • Ongoing Phase 3 trial analyses were also presented, indicating patients generally maintained quality of life with limited treatment-related toxicity.
  • Separate Phase 3 biomarker work was presented, suggesting blood-based signals could help identify patients more likely to benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010730PRIMZONEFULLFEED9729481) on June 01, 2026, and is solely responsible for the information contained therein.